<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for NKTR</title>
    <link />
    <description>Headlines for Nektar Therapeutics</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>A Hidden Reason Nektar Therapeutics's Future Looks Bright</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/06/19/a-hidden-reason-nektar-therapeuticss-future-looks/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 19 Jun 2013 01:02:09 GMT</pubDate>
    </item>
    <item>
      <title>Short Interest Drops 20.3% For NKTR</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11949882/1/short-interest-drops-203-for-nktr.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Thu, 13 Jun 2013 14:41:00 GMT</pubDate>
    </item>
    <item>
      <title>Why Progenics Is Poised to Plunge</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/06/12/why-progenics-is-poised-to-plunge/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 12 Jun 2013 09:35:00 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Presents Data on Oncology Candidates - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/100905/nektar-presents-data-on-oncology-candidates.aspx</link>
      <author>Zacks</author>
      <pubDate>Wed, 05 Jun 2013 21:40:01 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Announces Positive Preclinical Data for NKTR-214</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/06/3641489/nektar-announces-positive-preclinical-data-for-nktr-214.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 03 Jun 2013 09:07:17 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Announces Target-Specific Biomarkers Being Evaluated in Phase 3 BEACON Study of Etirinotecan</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/06/3639596/nektar-announces-target-specific-biomarkers-being-evaluated-in-phase-3-beacon-stu.aspx</link>
      <author>Benzinga</author>
      <pubDate>Sat, 01 Jun 2013 14:31:21 GMT</pubDate>
    </item>
    <item>
      <title>Data on AstraZeneca's Naloxegol - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/100082/data-on-astrazenecas-naloxegol.aspx</link>
      <author>Zacks</author>
      <pubDate>Thu, 23 May 2013 23:00:01 GMT</pubDate>
    </item>
    <item>
      <title>NKTR Crosses Below Key Moving Average Level</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11931664/1/nktr-crosses-below-key-moving-average-level.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Wed, 22 May 2013 16:37:00 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Therapeutics' CEO Presents at UBS Global Healthcare Conference (Transcript)</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1450081-nektar-therapeutics-ceo-presents-at-ubs-global-healthcare-conference-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Tue, 21 May 2013 12:00:02 GMT</pubDate>
    </item>
    <item>
      <title>Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented a</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/05/3607594/results-from-phase-iii-studies-of-naloxegol-for-treatment-of-opioid-induced-const.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 21 May 2013 09:26:00 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Posts Wider Loss, Maintains View - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/99452/nektar-posts-wider-loss-maintains-view.aspx</link>
      <author>Zacks</author>
      <pubDate>Wed, 15 May 2013 11:26:01 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Therapeutics Enters Oversold Territory (NKTR)</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11920216/1/nektar-therapeutics-enters-oversold-territory-nktr.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Fri, 10 May 2013 12:34:00 GMT</pubDate>
    </item>
    <item>
      <title>Nektar's CEO Discusses Q1 2013 Results - Earnings Call Transcript</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1422771-nektar-s-ceo-discusses-q1-2013-results-earnings-call-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 10 May 2013 00:20:03 GMT</pubDate>
    </item>
    <item>
      <title>Bayer Initiates Phase III Trial of BAY41-6551T, Delivered by a Pulmonary Drug Delivery System Develo</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3499414/bayer-initiates-phase-iii-trial-of-bay41-6551t-delivered-by-a-pulmonary-drug-deli.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 16 Apr 2013 05:52:21 GMT</pubDate>
    </item>
    <item>
      <title>3 Stocks to Get on Your Watchlist</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/04/10/3-stocks-to-get-on-your-watchlist-29/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 10 Apr 2013 11:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Positive Data on Nektar's NKTR-214 - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96555/positive-data-on-nektars-nktr-214.aspx</link>
      <author>Zacks</author>
      <pubDate>Mon, 08 Apr 2013 18:08:01 GMT</pubDate>
    </item>
    <item>
      <title>Here's Why Nektar Therapeutics's Latest Report Might Worry You</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/04/03/heres-why-nektar-therapeuticss-latest-report-migh/.aspx</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 03 Apr 2013 13:05:02 GMT</pubDate>
    </item>
    <item>
      <title>Several Big Growth Stories In Biotech: Keith Markey</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1308521-several-big-growth-stories-in-biotech-keith-markey.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 28 Mar 2013 20:13:07 GMT</pubDate>
    </item>
    <item>
      <title>What Is In The Future For Nektar?</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1291631-what-is-in-the-future-for-nektar.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 21 Mar 2013 08:06:34 GMT</pubDate>
    </item>
    <item>
      <title>Nektar Loss Widens, Gives Guidance - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/94245/nektar-loss-widens-gives-guidance.aspx</link>
      <author>Zacks</author>
      <pubDate>Thu, 07 Mar 2013 12:41:01 GMT</pubDate>
    </item>
  </channel>
</rss>
